B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
By A Mystery Man Writer
Description
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable
Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast
In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum
Digital Diabetes Management Market Size, Trends & Forecast
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
Apheresis Machines Market 2021: Comprehensive Study Explores
Digital Diabetes Management Market Size, Trends & Forecast
In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable
Apheresis Machines Market 2021: Comprehensive Study Explores
from
per adult (price varies by group size)